Analysis Carl Zeiss Meditec AG (0DHC)
5/26/2024
Analysis of Carl Zeiss Meditec AG (0DHC)
Carl Zeiss Meditec AG is showing a positive trend based on the recent data. The closing prices have been increasing steadily over the past few days, with the RSI indicator showing values above 30, indicating a bullish momentum. The MACD indicator is also showing positive values, with the MACD line crossing above the signal line.The moving averages (SMA, EMA, WMA) are all trending upwards, indicating a positive trend in the stock price. The stock has been trading above the moving averages, which is a bullish signal.
Overall, based on the technical indicators and moving averages, Carl Zeiss Meditec AG seems to be in an uptrend and could potentially continue to rise in the near future. However, it's always important to consider other factors such as market conditions and company news before making any investment decisions.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management strategies.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023, showing a healthy growth in profitability.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years, indicating growth in shareholder value.
7. The company has been able to maintain a stable number of outstanding shares, which is important for EPS calculations and shareholder value.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and shows a growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets, indicating a healthy financial position.
5. Shareholders' equity has shown a positive trend, with common stock and retained earnings contributing significantly.
6. The company has been managing its short-term and long-term debts effectively, with a good balance between current and non-current liabilities.
7. The accumulated depreciation on non-current assets suggests a consistent investment in long-term assets.
8. Overall, the company's financial health seems stable and improving over the years.
Earnings
The company's results for the most recent quarter, as of April 30, 2025, have not been provided at this time. The previous results from February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were reported after hours. The results from October 31, 2024, were not supplied at the time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.33.Main Statystic ðŸ§
The company's financials show a strong cash flow, with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet indicates a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a fiscal year ending on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44. The operating margin is 30.74%, with a return on assets of 22.07% and return on equity of 147.25%.In terms of stock statistics, the short ratio is 1.66, with 94.31 million shares shorted out of 15.31 billion float shares. The stock has an average 10-day volume of 52.90 million and an average 90-day volume of 62.82 million. Institutions hold 57.55% of shares, while insiders hold 5.22%. The stock price summary includes a beta of 1.264, a 50-day moving average of $173.69, and a 200-day moving average of $180.79. The 52-week range is between $164.08 and $199.62.
Valuation metrics show a PEG ratio of 26.21, forward P/E of 26.21, and trailing P/E of 29.43. The enterprise value is $2.95 trillion, with a price-to-book ratio of 39.18, price-to-sales ratio of 7.62, enterprise-to-EBITDA ratio of 22.75, and enterprise-to-revenue ratio of 7.73. The market capitalization stands at $2.91 trillion.
Regarding dividends and splits, the company has a payout ratio of 14.93% and a forward annual dividend rate of $1, with a trailing annual dividend yield of 0.51% and a forward annual dividend yield of 0.53%. The dividend date is May 16, 2024, with an ex-dividend date of May 10, 2024. The last split date was on August 31, 2020, with a 4-for-1 split. The 5-year average dividend yield is 0.73%.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include acquisitions, capital expenditures, and the sale/purchase of investments.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and years, with an increase compared to the previous year's EPS. This indicates potential growth and improvement in the company's financial performance according to analysts' projections.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest that the company has experienced significant growth in the past but is expected to see a more moderate growth rate in the coming years. The next year is expected to show a higher growth rate compared to the current year, and the next 5 years are projected to have a growth rate lower than the average of the past 5 years.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of 0DHC
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
